# 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

> **NCT04158245** · PHASE2 · COMPLETED · sponsor: **Tulane University** · enrollment: 9 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** 18F-fluciclovine PET Scan

## Key facts

- **NCT ID:** NCT04158245
- **Lead sponsor:** Tulane University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-30
- **Primary completion:** 2022-09-30
- **Final completion:** 2023-04-03
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04158245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04158245, "18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04158245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*